{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-119217","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.232809+00:00","generated_at":"2026-05-16T13:59:18.118659+00:00","sec_items":["1.01","3.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"INmune Bio extends poison pill rights agreement to December 31, 2026","bullets":["Amendment No. 5 to Rights Agreement dated Dec 5, 2025 extends expiration to Dec 31, 2026.","Expiration date will auto-extend for successive one-year terms unless Board decides otherwise.","Rights Agreement originally dated Dec 30, 2020 between INmune Bio and VStock Transfer LLC.","No other changes to terms of the shareholder rights plan were disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-119217","json":"https://secwatch.observer/filing/0001213900-25-119217.json","markdown":"https://secwatch.observer/filing/0001213900-25-119217.md","text":"https://secwatch.observer/filing/0001213900-25-119217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025119217/0001213900-25-119217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025119217/ea0268667-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:59:18.118659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}